We Love This Stock!
SciSparc Ltd. (NASDAQ: SPRC) already has a fully approved commercial product CannAmide, approved by Health Canada. CannAmide™ is recommended for use as an anti-inflammatory to help relieve chronic pain while the tablets will be marketed to pharmacies and other retail outlets across Canada.
This is incredible news as until now, op-i-oids are pretty much the only option for many people. But we all know the devastating effects op-i-oid abuse is wreaking on the world.
Cann-a-bis buds are covered in sticky, shining dots of resin, and in this resin are hundreds of therapeutic compounds that contribute to the effects and benefits of cann-a-bis.
In those compounds lies the secret to incredible potential.
Those hidden compounds the plant produces work together to create unique effects and benefits known as “the entourage effect.”
They can produce a synergy in the body to reduce inflammation and allow other dr-ugs to do their job.
THAT is a MASSIVE differentiator which makes SciSparc Ltd. (NASDAQ: SPRC) so unique and so compelling.
Leveraging the “entourage effect” the company has three powerhouse cann-a-bis-based dr-ugs in late development to help treat Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Autism Spectrum Disorder (ASD).
I WILL have more on this one soon.
Please visit the Full Report Here
Patent news issued today!